The FDA has approved Amylin's Byetta as a stand-alone diabetes drug. The company's CEO, Daniel Bradbury, discusses the approval and more with CNBC's Mike Huckman.
Topics:
Biotechnology | Pharmaceuticals
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT